Associated Papers
ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report.
Hsu C et al.
Jto Clinical and Research Reports, 2026
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.
Saint-Charles A et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Sustained Complete Response to Brigatinib in a Young Patient With ALK-Positive NSCLC Harboring I1171N Mutation Post-Alectinib Resistance.
Kapoor A et al.
Case Reports in Oncological Medicine, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of an ALK degrader for lorlatinib-resistant compound mutations.
Gao F et al.
European Journal of Medicinal Chemistry, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.
Zhao F et al.
International Journal of Biological Macromolecules, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
Farouk Sait S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical Sequence Revealed the Prevalence and Biological Significance of Somatic Pathogenic Variants in Thoracic Cancer: Implications for Germline Status.
Fukushima T et al.
Clinical Lung Cancer, 2025
Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report.
Yang G et al.
Anti-cancer Drugs, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report.
Huang X et al.
Frontiers in Oncology, 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Case Report: Metastatic colorectal cancer with ALK-CEP44 fusion and rapid resistance development.
Hofmann S et al.
Frontiers in Oncology, 2025
Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib.
Luo Y et al.
Frontiers in Oncology, 2025
Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors.
Gu J et al.
Frontiers in Pharmacology, 2025
Durable response with mutation-guided ALK inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report.
Chaudhry SS et al.
Rare Tumors, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Leporati R et al.
Tumori, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T et al.
Cancer Research Communications, 2024
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.
Bobin C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.
Wilson I et al.
Cancer Reports (hoboken, N.j.), 2024
Benefits for children with suspected cancer from routine whole-genome sequencing.
Hodder A et al.
Nature Medicine, 2024
Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer.
Xie Y et al.
Journal of Thoracic Disease, 2024
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
Wu L et al.
Journal of Translational Medicine, 2024
Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study.
Fang Z et al.
Journal of Thoracic Disease, 2024
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M et al.
Cancer Research Communications, 2024
Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
Inno A et al.
Clinical Lung Cancer, 2024
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X et al.
Computers in Biology and Medicine, 2024
Prolonged Disease Control Despite ALK Inhibitor Discontinuation in Advanced ALK-Positive NSCLC.
Hussain SA et al.
European Journal of Case Reports in Internal Medicine, 2024
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.
Balasundaram A et al.
Acs Omega, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Yoshida T et al.
Cancer Science, 2023
Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
Hunt AL et al.
The Oncologist, 2023
Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights.
Salifu EY et al.
Journal of Biomolecular Structure & Dynamics, 2023
Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report.
Saw SPL et al.
Jto Clinical and Research Reports, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER et al.
Nature Communications, 2023
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.
Yang S et al.
World Journal of Surgical Oncology, 2023